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ABSTRACT
Background: Eosinophilic oesophagitis (EO) is an
emerging yet increasingly prevalent disorder characterised
by a dense and selective eosinophilic infiltration of the
oesophageal wall. While EO is considered an atopic
disease primarily triggered by food antigens, disparities
between standard allergen testing and clinical responses
to exclusion diets suggest the participation of distinct
antigen-specific immunoglobulin E (IgE) in the pathophy-
siology of EO.
Aim: To find evidence for a local IgE response.
Methods: Endoscopic biopsies of the distal oesophagus
of atopic and non-atopic EO and control individuals (CTL)
were processed for immunohistochemistry and immuno-
fluorescence to assess the presence of B cells, mast
cells, and IgE-bearing cells. Oesophageal RNA was
analysed for the expression of genes involved in B cell
activation, class switch recombination to IgE and IgE
production, including germline transcripts (GLTs), activa-
tion-induced cytidine deaminase (AID), IgE heavy chain
(Ce) and mature IgE mRNA using polymerase chain
reaction and microarray analysis.
Results: Regardless of atopy, EO showed increased
density of B cells (p,0.05) and of IgE-bounded mast cells
compared to CTL. Both EO and CTL expressed mGLT,
eGLT, c4GLT, AID, Ce and IgE mRNA. However, the
frequency of expression of total GLTs (p=0.002), eGLT
(p=0.024), and Ce (p=0.0003) was significantly higher
in EO than in CTL, independent of the atopic status.
Conclusion: These results support the heretofore
unproven occurrence of both local immunoglobulin class
switching to IgE and IgE production in the oesophageal
mucosa of EO patients. Sensitisation and activation of
mast cells involving local IgE may therefore critically
contribute to disease pathogenesis.
Eosinophilic oesophagitis (EO) is a chronic inflam-
matory disorder, restricted to the oesophagus,
whose pathogenesis is poorly understood. Studies
from North America,
12Europe
3 and Australia
4 have
indicated that EO is a growing health problem
worldwide with an annual incidence of >1i n
10 000.
5 Patients with primary EO often report
symptoms (chest and abdominal pain, dysphagia,
heartburn, vomiting, and food impaction) also
observed in gastro-oesophageal reflux disease
(GORD) or chronic oesophagitis. However, in
contrast to GORD patients, EO patients are
predominantly males,
3 have a familial pattern of
inheritance,
6 do not respond to treatment with
proton pump inhibitors (PPIs), have normal pH
monitoring,
78show extensive epithelial hyperpla-
sia and higher density of eosinophils (.15 peak
eosinophils/high-power field) in the oesophageal
epithelium, and over-express a unique transcrip-
tome including the eosinophil chemokine eotaxin-
3.
91 0
Several lines of evidence support the view that
EO is an atopic disorder.
11 12 Most patients with EO
(,75% of cases) show signs of atopy, defined by
reactivity to allergens by skin-prick testing (SPT) or
identification of specific IgE in serum.
51 21 3
Furthermore, EO appears to be primarily food
antigen-driven since .90% of patients achieve
complete remission following an elemental diet-
based nutrition.
14 However, despite the high rate of
sensitisation to specific food antigens, the benefit
of removing SPT-based exclusion diets is com-
monly unsatisfactory.
15 16 Perhaps the identifica-
tion of antigen sensitisation via cutaneous testing
is not reflective of the presumably IgE bound to
mast cells (or basophils) in the oesophageal
mucosa.
Mast cells are resident cells of the oesophagus,
shown previously to be increased in number and to
correlate with eosinophil counts and eotaxin-3 in
the mucosa of EO patients.
10 17 In addition, the
transcription of some mast cell-specific genes, such
as carboxypeptidase A3, high-affinity IgE receptor
(FceR1) and tryptase-a is higher in oesophageal
biopsies from patients with EO compared with
healthy controls.
10 These findings, together with
the presence of mast cells in the oesophagus of
patients with EO,
10 17–19 suggest a putative role for
mast cell-mediated hypersensitivity in the patho-
genesis of EO.
The oesophageal mucosa displays a strong
immunological capacity conveyed via a diversity
of resident immune cell types,
18 20 well represented
by its known ability to recruit acute inflammatory
cells and eosinophils.
21 22 In particular, the presence
of interleukin 4 (IL4) and IL13,
22 B cells
18 19 and of
cells that are potentially CD40L
+ (eg, T cells and
mast cells) in the oesophagus supports its partici-
pation in allergen sensitisation and IgE production,
highlighting a potential role for B lymphocytes and
mast cells in this disease. Following antigen
stimulation, mature B lymphocytes undergo class
switch recombination (CSR) by changing the C
region of the Ig H chain (CH) with a downstream
region on human chromosome 14,
23 therefore
improving the antibody effector function and
contributing to the maturation of the humoral
response.
24 25 Induction of CSR to IgE requires
mature B cells, IL4 or IL13, cognate help by CD40-
L
23 24 and upregulation of activation-induced cyti-
dine deaminase (AID).
26 27 CSR involves the tran-
scription of germ-line genes, DNA recombination
within the heavy chain locus producing e circular
Oesophagus
12 Gut 2010;59:12–20. doi:10.1136/gut.2009.178020transcripts, and the synthesis of immunoglobulin mature
mRNA that is translated into protein.
23 Although this phenom-
enon has been generally assumed to be restricted to lymphoid
organs,
28 29 recent studies have demonstrated that other tissues
under constant antigenic challenge such as the intestinal,
30 31
nasal
32 and bronchial
33 mucosa support isotype switching and
IgE production.
We hypothesised that the oesophageal mucosa acts as a site
for IgE generation in EO. We examined a cohort of paediatric
patients and studied B cell levels in the oesophageal mucosa, and
the molecular steps involved in CSR to IgE. Our results identify
the human oesophagus as an immunologically active tissue with
regard to B cell antibody production, suggesting a role for B
lymphocytes and local IgE synthesis in EO and implicating local
IgE-mediated mast cell degranulation as an important con-
tributor to EO pathogenesis.
MATERIALS AND METHODS
Oesophageal biopsies and patient characteristics
Patients were retrospectively selected without any regard to age,
atopic status, or gender from our database at the Division of
Pathology and Laboratory Medicine at Cincinnati Children’s
Hospital Medical Center. Biopsy specimens were collected from
the distal oesophagus, fixed in formalin and processed for
pathological analysis with haematoxylin & eosin (H&E)
staining. Diagnosis of EO was established by a pathologist
based on a maximum eosinophil count of >15 eosinophils per
high-power field (hpf, 6400), the presence of inflammatory
infiltrate, and the hyperplasia of the basal epithelial layer. The
control group (CTL) included patients with symptoms typical
of GORD and EO, most of them under PPI therapy, which
showed normal endoscopic and histological evaluation and the
presence of (5 eosinophils/hpf. We first studied the cellular
infiltrate and the expression of B cell-related genes in patients
from our database regardless of therapy, and thereafter selected a
cohortofpatientswithoutcorticosteroidsordiettherapytoassess
molecular markers of CSR and IgE synthesis. The detailed clinical
characteristics of the selection of EO and CTL patients including
eosinophil counts in the oesophageal epithelium, atopic status
and therapy are shown in table 1. Patients suffering from asthma,
allergic rhinitis or eczema were defined as atopic. Due to the low
amount of biological material derived from endoscopic oesopha-
geal biopsies from paediatric patients, not all samples could be
processed for all experimental procedures.
Immunohistochemistry
Formalin-fixed, paraffin-embedded biopsies were sectioned at
4 mm and stained with antibodies following standard proce-
dures. B lymphocytes were identified with mouse anti-human
CD20 (Dako, XXXXX, California, USA), and mast cells with
mouse anti-human tryptase (Cell Marque, Rocklin, California,
USA). Staining was developed with the LSABH2 System-HRP
(Dako, Carpinteria, California, USA). Sections of human tonsils
and nasal polyp were used as positive control for CD20 or
tryptase staining, respectively. The primary antibody was
omitted as a negative control. One biopsy section from each
patient was subjected to CD20 or tryptase staining.
Morphometric analysis was performed for quantification of
CD20
+ cells using the Metamorph Imaging system (Universal
Imaging, West Chester, Pennsylvania, USA). Total stained cells
and total surface area were quantified in the three compart-
ments of the oesophageal mucosa: the epithelium, the vascular
papillae (projections of the lamina propria towards the under-
surface of the epithelium)
35 and the lamina propria, and results
are expressed as number of positive cells per mm
2 of tissue.
Tryptase
+ cells were counted in at least 10 non-overlapping
Table 1 Clinical characteristics of patients with eosinophilic oesophagitis and of control patients
Patient no.
Age (years)/
Gender Eosinophil peak/hpf Total IgE (ng/ml) Asthma Allergic rhinitis Eczema Therapy
Eosinophilic
oesophagitis (n=11)
1 6/M 35 NA ++2 b2-Agonist, antihistaminic
2 10/M 85 148 2 + 2 PPI, antihistaminic
3 7/M 50 20 NA + 2 Antibiotic
4 7/M 82 NA +++PPI, b2-agonist,
antihistaminic
5 13/F 91 1590 +++PPI, b2-agonist,
antihistaminic
6 4/F 28 420 22+ b2-Agonist, antihistaminic
7 6/F 71 NA 2 + 2 PPI, antihistaminic
8 16/M 24 316 222None
9 14/M 76 NA 222PPI, LTRA
10 3/M 68 17 222PPI
11 2/M 51 347 222PPI
Controls (n=8)
12 2/M 0 216 ++2 Antibiotic
13 16/F 0 402 ++2 PPI
14 2/M 5 5 2 + 2 PPI, antihistaminic
15 2/M 2 16 2 ++PPI
16 8/M 0 NA ++NA PPI
17 7/M 2 NA 222PPI, b2-agonist
18 8/M 3 NA 222None
19 6/M 0 5 222PPI, antihistaminic
Serum IgE concentration in control individuals was 96 ng/ml.
34
F, female; hpf, high-power, field; IgE, immunoglobulin E; LTRA, leukotriene receptor antagonist; M, male; NA, not available; PPI, proton pump inhibitor.
Oesophagus
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positive cells per hpf.
Immunofluorescence
Double immunofluorescence staining was performed in side-
mounted paraffin sections. Mast cells were identified with
rabbit anti-human CD117 (Cell Marque) and IgE-bearing cells
with chicken anti-human IgE (Genway Biotech, San Diego,
California, USA) primary antibodies. Secondary antibodies were
Alexa Fluor 488-labelled goat anti-rabbit (Invitrogen, Carlsbad,
California, USA) and biotinylated donkey anti-chicken (Jackson
Labs, West Grove, Pennsylvania, USA), following Alexa Fluor
Figure 1 Detection of B cells in the
oesophageal mucosa. (A) Representative
micrographs of the CD20 staining in the
epithelium, the vascular papillae and the
lamina propria of the oesophageal
biopsies of EO and CTL subjects. (B)
Density of B cells in each compartment of
the oesophageal biopsies of EO (n=21)
and CTL (n=12) groups. Atopic (open
symbols) and non-atopic patients (dark
symbols) are indicated. The lines
represent the median value in each group.
Groups were compared using the non-
parametric Mann–Whitney U test and p
values are indicated. (C) Microarray
analysis of the transcripts of upregulated
B cell-related genes in the oesophageal
biopsies of EO (n=13) and CTL (n=13)
patients. RNA from each patient was
subjected to chip analysis using
Affymetrix Human Genome U133 Plus 2.0
Gene Chips. Affymetrix accession number
of genes and their fold change expression
in EO with respect to CTL are indicated.
Statistical analysis was performed using
the Welch T test; p values are indicated
(n=13 for EO and CTL groups). CTL,
control; EO, eosinophilic oesophagitis.
Figure 2 Mast cell counts in the
oesophageal epithelium of EO and CTL
patients. (A) Atopic (open symbols) and
non-atopic patients (dark symbols) are
indicated. The lines represent the median
value in each group. The maximum cell
count per hpf in each group was
compared using the Mann–Whitney U
test and the p value is indicated (EO
n=18; CTL n=8). (B) Correlation
between density of B cells and mast cells
counts in the oesophageal epithelium of
EO and CTL patients was calculated with
the Spearman rank correlation test
(p=0.0015; r
2=0.554). Different units in
each axis derive from the different
methodology to assess cell counts. CTL,
control; EO, eosinophilic oesophagitis.
Oesophagus
14 Gut 2010;59:12–20. doi:10.1136/gut.2009.178020594 labelled streptavidin (Invitrogen). Slides were cover-slipped
using antifade medium containing 49,6-diamidine-29-phenylin-
dole dihydrochloride (DAPI) (Prolong Gold; Invitrogen) and
assessed and photographed using an RT Slider digital camera
(Diagnostic Instruments, Sterling Heights, Michigan, USA)
mounted on an E600 fluorescence microscope (Nikon
Instruments, Melville, New York, USA). Nasal polyp biopsy
sections from an allergic patient were used as positive control
tissue. Isotype-matched control antibodies were used as
negative control. Results are expressed as the maximum number
of stained cells per reticle area using a Nikon CF1 610 eyepiece.
RNA isolation and DNA microarray analysis
Each biopsy from the distal oesophagus was immediately
immersed in RNAlater (Qiagen, Germantown, Maryland, USA)
and stored at 4uC. Total mRNA was isolated using the RNAeasy
Mini Kit (Qiagen) and hybridisation to DNA microarray was
performed by the Microarray Core. Microarray analysis and
assessment of transcripts from B lymphocyte-related genes were
performed as previously described.
36
Reverse transcription polymerase chain reaction and PCR
analysis
The RNA samples (500 ng) were subjected to reverse transcrip-
tion analysis using Inscript reverse transcriptase (Bio-Rad
Laboratories, Hercules, California, USA) following the manu-
facturer’s instructions. Germ-line transcripts (GLTs) from
eGLT, mGLT, c1GLT and c4GLT, and AID mRNA were
amplified with validated primer sets.
32 Mature IgE mRNA was
amplified with primers JH2
37 and CeR( 5 9-CAGGACGAC
TGTAAGATCTTCACG). To assure the integrity and to control
the load of cDNA, glyceraldehyde-3-phosphate dehydrogenase
was amplified with primers GAPDH-F (59-TGGAAATCCC
ATCACCATCT) and GAPDH-R (59-GTCTTCTGGGTGGCA
GTGAT). PCR was run in a 23 ml reaction in the ready-to-use
Supermix PCR mixture (Invitrogen) containing 3 ml of template
and the corresponding primers at 0.22 mmol/l. For AID
amplification, the two rounds of PCR were: denaturation at
96uC for 10 min, following 25 cycles of denaturation at 96uC for
1 min, annealing at 60uC for 1 min and elongation at 72uC for
2 min, and a final extension at 72uC for 5 min. Similar
conditions were used to amplify GLT and IgE mRNA, with
30 s time on each step of the 50 or 45 PCR cycles, respectively,
and annealing temperature of 60uC for eGL, 55uC for mGLT,
c1GLT and c4GLT, and 57uC for IgE mRNA. The human
Burkitt’s lymphoma B cell line Ramos (RA1; ATCC, Manassas,
Virginia, USA) was used as positive control for AID and for
eGLT expression, the later after stimulation with IL4 (10 ng/ml)
and soluble CD40 ligand (5 mg/ml) for 48 h. The human IgE-
bearing cell line U266B1 (ATCC) was used as positive control
for IgE mRNA. Nuclease-free water was used as negative
control.
Real-time PCR analysis
IL4, IL13 and the heavy chain of the IgE gene (Ce) were first
amplified by PCR and sequenced to confirm their identity. PCR
products were used to build a standard curve for the real-time
PCR reaction by means of the LightCycler instrument and
LightCycler FastStart DNA Master SYBR Green I as a ready-to-
use reaction mix (Roche Diagnostics, Indianapolis, Indiana,
USA). Primers used were: IL4F (59-ACATCTTTGCTGCCT
CCAA), IL4R (59-AGGCAGCGAGTGTCCTTCT); IL13F (59-
ACAGCCCTCAGGGAGCTCAT), IL13R (59-TCAGGTTGATG
CTCCATACCAT); CeF( 5 9-CACGCTCTCTGGTCACTATG)
and CeR (see above). Amplification conditions were denatura-
tion at 96uC for 10 min, followed by 40 cycles of denaturation
at 96uC for 5 s, annealing at 60uC (IL4 and IL13), or 65uC( C e)
for 15 s and elongation at 72uC for 15 s. The expression of the
different transcripts was normalised to GAPDH, and results are
expressed as fold induction with respect to the CTL group.
Statistical analysis
All histological samples were randomly coded, and sections were
counted blinded, independent of the clinical protocol. The x
2
test was used for comparison of frequencies of GLTs and IgE
transcripts. Numeric variables were analysed with the non-
parametric Mann–Whitney U test. Correlation between CD20
+
cells and tryptase
+ counts was analysed using the Spearman
rank correlation test. A value of p,0.05 was considered
statistically significant.
RESULTS
B lymphocytes and mast cells in the oesophageal mucosa
The presence of B cells was rarely detected in the epithelium of
CTL patients. However, the oesophageal epithelium of EO
patients showed significantly higher density of scattered B
lymphocytes, mainly in the peripapillary area, compared to CTL
patients. The vascular papillae of EO samples also showed more
CD20
+ cells than the CTL samples, and no difference was
observed in the lamina propria (fig 1A,B). Interestingly, atopic
and non-atopic patients followed similar distribution within the
EO and CTL groups. Furthermore, microarray analysis revealed
that EO patients have higher expression of B cell-related genes
than CTL subjects (fig 1C) including immunoglobulin lambda
Figure 3 Analysis of the expression of
IL4 (A) and IL13 (B) in oesophageal
biopsies from EO and CTL patients. Atopic
(open symbols) and non-atopic patients
(dark symbols) are indicated. Each mRNA
value was normalised to GAPDH mRNA
expression from the same cDNA and is
expressed as fold change with respect to
the CTL group. The lines represent the
median value in each group. EO (n=11)
and CTL (n=628) groups were
compared using the Mann–Whitney U
test. Values of p are indicated. CTL,
control; EO, eosinophilic oesophagitis;
GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; IL, interleukin.
Oesophagus
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bulin J polypeptide and B cell RAG-associated protein (with a
12.3-, 12.1-, 8.8- and 1.9-fold increase, respectively (p,0.001)).
Mast cell infiltration was also increased in EO compared to CTL
samples (fig 2), as previously shown
10 18 19 with similar distribu-
tion of atopic and non-atopic subjects within each group.
Notably, the density of CD20
+ cells positively correlated with
mastcells (p=0.0015;r
2=0.554;fig2B), but not witheosinophils
in the epithelium (data not shown). Positive control staining
procedure for human tonsils or nasal polyp revealed the presence
of B cells and mast cells, respectively, and negative control
procedure did not detect any positive cells (data not shown).
Expression of IL4 and IL13
Real-time PCR demonstrated that IL4 mRNA expression was
increased in EO compared with CTL, particularly in a subset of
EO patients (fig 3A), with no difference related to atopy, and
that IL13 mRNA was over-produced in EO, as previously
shown.
22 Interestingly, atopic and non-atopic EO patients had
comparable levels of IL13 mRNA (fig 3B).
Expression of GLT in the oesophageal mucosa
The transcription of GLTs is essential for CSR and is the first
step in the commitment of B cells to the synthesis of IgG, IgA
and IgE. We detected eGLT, mGLT and c4GLT (fig 4) but not
aGLT, c1GLt or c3GLT (data not shown) in oesophageal
biopsies. The frequency of expression of total GLTs was
higher in EO patients (p=0.012), being individually nine of
11 EO, and three of eight CTL for eGLT (p=0.024); six of 11
EO, and four of eight CTL for mGLT (p=0.456); and five of 11
EO, and one of eight CTL for c4GLT (p=0.064).
Interestingly, GLTs were similarly detected in both atopic
and non-atopic EO patients. All PCR products were gel-
extracted and sequenced to confirm their identity with the
corresponding IgH chain sequences present in GeneBank (data
not shown).
Figure 4 Analysis of the expression of
GLTs in oesophageal biopsies of EO and
CTL patients. Patients are divided into
atopic (EO-A, n=7; CTL-A, n=5) and
non-atopic (EO-NA, n=4; CTL-NA, n=3)
groups. The eGLT, 379 bp; mGLT, 529 bp;
and c4GLT, 505 bp bands were PCR
amplified from oesophageal biopsies of
EO and CTL patients. GAPDH was
amplified to control cDNA loading. Lanes
+ and 2 correspond to PCR positive and
negative controls, respectively. A 1 kb
plus DNA ladder was loaded in all cases.
Gels are representative of one of three
independent PCR amplifications yielding
similar results. CTL, control; EO,
eosinophilic oesophagitis; GAPDH,
glyceraldehyde-3-phosphate
dehydrogenase; GLTs, germ-line
transcripts; PCR, polymerase chain
reaction.
Figure 5 Analysis of the expression of
AID in oesophageal biopsies of EO and
CTL patients. Patients are divided into
atopic (EO-A, n=7; CTL-A, n=5) and
non-atopic (EO-NA, n=4; CTL-NA, n=3)
groups. The 335 bp AID mRNA band was
amplified in a semi-nested PCR. GAPDH
was amplified to control cDNA loading.
Lanes + and 2 correspond to PCR
positive and negative controls,
respectively. The two negative – lanes
indicate first-round and second-round
PCR-negative controls. A 1 kb plus DNA
ladder was loaded. Gels are
representative of one of three
independent PCR amplifications yielding
similar results. AID, activation-induced
cytidine deaminase; CTL, control; EO,
eosinophilic oesophagitis; GAPDH,
glyceraldehyde-3-phosphate
dehydrogenase; PCR, polymerase chain
reaction.
Oesophagus
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The enzyme AID catalyses the initial step of CSR in germinal-
centre B cells, and has recently been detected outside lymphoid
structures.
32 33 Here, we detected AID expression in biopsies
from both groups, indicating the potential of the oesophageal
mucosa to undergo CSR (fig 5). PCR products from all samples
were sequenced and identified as human AID mRNA (data not
shown).
Expression of IgE heavy chain mRNA in the oesophageal mucosa
All EO subjects showed higher expression of Ce than CTL
patients, as determined by quantitative PCR (fig 6). The
amplified PCR product is representative of either the sterile
transcripts or the mature IgE mRNA, and is increased in biopsies
from both atopic and non-atopic EO patients. These data
confirm, at least at the mRNA level, that local IgE expression is
a feature of the oesophageal mucosa of EO, regardless of the
atopic status.
Expression of mature IgE mRNA in the oesophageal mucosa
The final step of CSR is antibody production. Mature IgE
mRNA was detected in five of 11 EO, regardless of atopy, and in
one of eight CTL subjects (fig 7). Differences in the frequency of
expression did not reach statistical significance between EO and
CTL (p=0.0635). Importantly, and consistent with the data
presented herein, detection of mature IgE mRNA suggests in
situ production of IgE in the oesophageal mucosa, independent
of the atopic status of the patient.
Detection of IgE-bearing cells in the oesophageal epithelium
We detected three different cell populations in the oesophageal
epithelium based on IgE and CD117 positivity (fig 8). IgE
+ cells
were detected only in EO and mast cells were present in both
groups; however, only the EO group showed IgE-bearing mast
cells. Of the total intraepithelial mast cells, the percentage of
IgE
+ cells was increased in atopic compared to non-atopic EO
patients (85.6%; 95% CI, 70 to 100; and 43.8%, 95% CI 5.2 to
82, respectively, p,0.05). Notably, the epithelium contained a
population of IgE
+ CD117
2 cells which was absent in CTL
subjects.
DISCUSSION
Eosinophilic oesophagitis is a chronic inflammatory disease in
which the presence of mediators such as IL5, IL13 and eotaxin,
the cellular infiltrate (eosinophils, mast cells and lymphocytes),
and the association with allergic disorders, all point to a Th2-
associated disease. A prominent feature of the Th2 immune
response is antibody production; however, the participation of B
cells in the pathogenesis of EO has not been extensively studied,
probably because of the low amount of infiltrating B cells as
compared with other immunocytes in the oesophageal epithe-
lium. Our study also shows that B lymphocytes are moderately
increased, consistent with studies in adult EO patients,
18 19
suggesting a similar pathogenic process in both adults and
children. Notably, since B cell infiltration may mainly occur
through the vascular supply of the epithelium, the increase in B
lymphocytes in the vascular papillae, consistent with that of the
epithelium, suggests that B cell recruitment is an active process
in the oesophageal mucosa in EO disease. Furthermore,
differential expression of immunoglobulin genes and other B
cell genes in EO compared to CTL subjects, together with IgE
production in the oesophageal mucosa, highlight B cells as
important contributors to EO pathogenesis.
CSR has been restricted to lymphoid tissues; however, recent
studies have proved this phenomenon at certain mucosal
sites.
32 33 The present study has discovered the expression of
GLT, AID, Ce and IgE mRNA in the human oesophagus,
providing the first evidence for local class switching to IgE and
IgE production, and actually indicating that the oesophageal
mucosa is primed for switching to IgE in EO. GLT expression
demonstrates the potential of B cells to undergo CSR, but it
does not provide definitive evidence that switching has actually
occurred.
38 In order to confirm the ongoing process, the presence
of either switch circles or circular transcripts needs to be
demonstrated.
27 39 However, since none of those molecular
markers were detected in EO biopsies (data not shown), we
cannot exclude the possibility that B cells switched elsewhere
and migrated to the oesophagus. Nevertheless, the expression of
switch circles and circular transcripts is transient, and they are
not detected unless switching has taken place recently.
38 In
order to detect ongoing switching, it may be necessary to collect
biopsies precisely at the time of exposure to the allergen, as has
been done in rhinitis patients during the allergy season.
32 In our
study, specimen collection was performed during the course of
the disease, and did not take into account whether patients
were avoiding exposure to specific foods prior to the endoscopy;
indeed, as part of the preparation, patients are fasted overnight.
This may explain why switch circles or circular transcripts were
undetectable in our samples. According to the hypothesis that
switching already occurred when biopsies were collected,
CD40L was not upregulated in EO (data not shown), as it is
rapidly and transiently expressed on recently stimulated T
helper cells and antigen-presenting cells upon activation.
40 41
Atopy is more prevalent in subjects who have EO than in the
general population.
61 2 Clinical studies have shown a high
prevalence of atopic diseases in EO patients.
61 3In our study,
rhinitis had the highest prevalence among atopic manifestations
(55%), highlighting a possible link between the immune
response in the respiratory tract and the oesophageal mucosa.
Notably, intranasal, but not oral or intragastric allergen
challenge induces experimental EO,
42 suggesting a role for
inhaled allergens. Nonetheless, not all EO patients have clinical
Figure 6 Analysis of the expression of Ce by real-time PCR in the
oesophageal biopsies of EO and CTL patients. Atopic (open symbols) and
non-atopic patients (dark symbols) are indicated. Each mRNA value is
normalised to GAPDH mRNA expression from the same sample and is
expressed as fold increase compared to the CTL group. The lines
represent the median value in each group. EO (n=11) and CTL (n=8)
groups were compared using the Mann–Whitney U test. The p value is
indicated. CTL, control; EO, eosinophilic oesophagitis; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; PCR, polymerase chain
reaction.
Oesophagus
Gut 2010;59:12–20. doi:10.1136/gut.2009.178020 17manifestations of atopy or show positivity to SPT and this fact
led us to analyse the Th2 response in atopic and non-atopic EO
patients and to compare it with the same two groups in CTL
patients. Interestingly, the recently identified EO transcript
signature has been proven to be remarkably conserved between
patients despite their age, sex, familial inheritance pattern and
Figure 7 Analysis of the expression of
mature IgE mRNA in oesophageal
biopsies of EO and CTL patients. Patients
are divided into atopic (EO-A, n=7; CTL-
A, n=5) and non-atopic (EO-NA, n=4;
CTL-NA, n=3) groups. The 412 bp IgE
band was PCR amplified from
oesophageal biopsies of EO and CTL
patients, and GAPDH was amplified to
control cDNA loading. Lanes 2 and +
correspond to PCR negative and positive
controls, respectively. A 1 kb plus DNA
ladder was loaded. Gels are
representative of one of three
independent PCR amplifications yielding
similar results. CTL, control; EO,
eosinophilic oesophagitis; GAPDH,
glyceraldehyde-3-phosphate
dehydrogenase; PCR, polymerase chain
reaction.
Figure 8 Detection of IgE
+ and CD117
+
cells in the oesophageal epithelium by
double immunofluorescence. (A)
Representative micrographs of the
oesophageal epithelium where IgE-
bearing cells (red) and mast cells (green)
are identified (arrow head). An example of
CTL and EO biopsies (a and b
micrographs, respectively) is shown,
where epithelial hyperplasia, elongation of
the vascular papillae (P) and eosinophils
(asterisk) are detected (low-power field,
6200). The three identified populations
are shown in groups of three micrographs
each, at high-power field (6600):
IgE
+CD117
+ (c, d, e); IgE
+CD117
2 (f, g, h);
IgE
2CD117
+ (i, j, k). (B) Quantification of
the cell populations based on IgE and
CD117 positivity in the oesophageal
epithelium of EO (n=16) and CTL (n=7)
patients. The maximum number of
positive cells per reticle is represented in
each group. Atopic (open symbols) and
non-atopic patients (dark symbols) are
indicated. CTL, control; EO, eosinophilic
oesophagitis.
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of EO have a common underlying pathogenesis.
61 0Those results
imply that the present study’s findings of accumulation of B
cells expressing molecular markers of CSR and detection of IgE
production would be comparable across both clinically defined
atopic and non-atopic EO patients. Indeed, and importantly,
perhaps ‘‘non-atopic’’ EO patients are actually atopic, but to a
lesser extent.
IL4 and IL13 have a key role in the induction of IgE switching
by stimulating transcription from the germline promoter site of
IgE, via STAT6 sites,
23 and are also B cell proliferating factors.
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Here we confirmed over-expression of IL13 mRNA in EO
22 and
demonstrated that transcription of IL13 is not influenced by the
atopic status of the patient. We have previously shown that the
expression of IL4 in EO patients is similar to control patients
although there was great heterogeneity in levels,
22 perhaps
because, in that previous study, patients with EO were selected
regardless of therapy. However, when selecting non-corticoster-
oid and non-dietary treated EO patients, IL4 mRNA proved
higher in EO than in CTL patients. Importantly, the participa-
tion of IL4 in promoting Th2 responses and stimulating class
switching to IgG4 and IgE
23 44 is suggested here, as demonstrated
by the expression of eGLT and c4GLT in EO subjects.
The presence of IgE
+ cells in the oesophageal epithelium has
been shown previously in EO, and it has been assumed that
those IgE-bearing cells were all mast cells.
17–19 Herein, we
demonstrate that IgE-sensitised mast cells are a feature of the
EO epithelium, and also that the percentage of mast cells linked
to IgE is increased in atopic compared to non-atopic EO
patients. Mechanisms other than antigen cross-linking of IgE on
the surface also activate mast cells to release mediators. Of
importance to EO, eosinophils and mast cells both secrete
mediators relevant for mutual activation and survival.
45 In our
study, two populations of intraepithelial mast cells were
detected based on IgE surface positivity, suggesting different
coexisting mechanisms of activation of mast cells in EO.
Notably, the correlation between CD20
+ cells and tryptase
+
cells, the expression of IgE mRNA and the density of
IgE
+CD117
+ in EO, suggest that IgE-mediated mast cell
activation importantly contributes to disease pathogenesis.
Of interest, we report a population of IgE-bearing cells lacking
CD117 expression. Eosinophils could account for this popula-
tion, since they express FceRI and FceRII.
46 However, they are
highly autofluorescent, and observation under a fluorescence
microscope confirmed that none of them were bound to IgE.
Memory B cells and plasmablasts can express IgE and are likely
to represent that IgE
+CD117
2 population. In patients with
allergic rhinitis, approximately 4% of the B cells and 15% of
plasma cells express IgE in the nasal mucosa and, in that
situation, it has been suggested that the maturation of IgE-
expressing B cells (activated or memory) to IgE-producing
plasma cells takes place locally.
47 The presence of B cells and of
IgE
+ cells in the oesophageal epithelium has been proven
previously.
17–19 In our study, the appearance of B cells primed
to isotype switch and the detection of IgE mRNA, led us to
hypothesise that mature B cells are locally challenged by
allergen, followed by the formation of IgE-memory B cells and
IgE plasmablasts. In keeping with this, we also showed
increased expression of immunoglobulin and stimulating B cell
genes in EO. However, we do not exclude the possibility that
already stimulated B lymphocytes at other mucosal sites
infiltrate the epithelium where, upon allergen stimulation, they
locally mature to IgE plasmablasts. Notably, the high rate of
transcription of the IGJ gene in EO biopsies, points at
plasmablasts as candidates for those IgE
+CD117
2 cells, since
the Ig J chain gene is expressed only after the terminal
differentiation of B cells towards plasma cells.
48
In summary, we have demonstrated increased B cells and
expression of molecular Ig machinery (eg, Ig genes and
recombination enzymes) in the oesophageal mucosa of paedia-
tric patients with EO regardless of the atopic status.
Furthermore, we have determined that IgE
+ cells (especially
mast cells) are a specific feature of EO compared with control
individuals. As such, we propose that the oesophageal mucosa is
a site for initiation and development of humoral responses.
These results offer an explanation for the dissociation between
skin-prick test results and food elimination diets in EO.
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